Lavni Varyani’s Post

Did you know that there are four regulatory pathways that you can use in Saudi Arabia? 1️⃣ Standard route - The most used pathway historically, and the pathway for generics and non-priority products - authorization within 365 days 2️⃣ Abridged pathway - Used for products with either FDA or EMA authorization - authorization within 60 days 3️⃣ Verification pathway - We also have the verification pathway. Now, this can be used if you have the FDA AND EMA approval - authorization within 30 days 4️⃣ Breakthrough pathway - Neither EMA NOR FDA authorization - authorization within 60 days Interested in learning more? Drop a note below! #Regulatory #Access #Authorization #SaudiArabia

The time is now for emerging markets. For years, the grouping of Saudi Arabia into an 'emerging markets' segment has bothered me. For those of us who live and breathe the region every day, we know it's far from the case. We have well and truly emerged, and our healthcare structures, systems, and regulatory processes demonstrate this change in action every single day. I found the same to be the case on a recent visit to China, a population that is far bigger and with more diversity, but with unparalleled technology that is at par or superior to more traditional manufacturing hubs. Pharma is at a risk of falling behind (yet again) if a traditional (and somewhat archaic) model is followed (yet again). Join Neil Grubert and I this Wednesday at 2PM BST / 5PM GST to explore this topic and get answers to your regional questions. ➡ Register now: https://lnkd.in/dhzAQWYy

Have you signed up? Neil Grubert and I are joining forces next week to discuss the key topic - "Have Emerging Markets Finally Emerged?" - a topic that I'm passionate about. Join us as we explore what biopharma companies need to do NOW to generate long-term growth coming from markets that are well and truly trailblazers in the industry. ➡ Register now: https://lnkd.in/dhzAQWYy

🗣 I speak to biopharma companies every single day. 🏔 It's what motivates me. 💊 The field that we're in can be daunting, and I make it my responsibility to work with these biopharma companies to support them getting their products to patients. Ultimately, that's what matters. 🇸🇦 Over the last few years, we've seen the market shift in affordability and where investments are coming from - and in our region, Saudi is a big driving force behind that. 🇨🇳 Having spoken to Neil Grubert recently, we were discussing not just this, but the fact that China, amongst other markets, is currently making huge strides in pharma - something that Pharma BP has been seeing as well with biopharma manufacturers from China seeking support in their GCC market access strategies. 🌟 It got us thinking about emerging markets. These markets that have been grouped into this 'emerging markets' segment have well and truly... emerged. 🔛 Join us as we discuss the implications of this and what the pharma industry needs to do not to fall behind. 🔜 Register now at: https://lnkd.in/dhzAQWYy

Eid Mubarak to everyone that is celebrating this auspicious occasion!

Developing a groundbreaking drug is only half the battle. 🇸🇦 In Saudi Arabia's evolving healthcare landscape, #PatientExperience tracking will be key to successful #ClinicalTrials and post-market adoption. Here's why: 🏔 Uncover real-world challenges: Go beyond clinical data to understand how #TrialDesign, medication access, and #communication impact patient experience in Saudi Arabia. 🏣 Boost #TrialRetention: Identify and address pain points early-on, leading to higher patient satisfaction and increased trial completion rates. 📈 Optimize post-launch success: Gain valuable insights to shape #PatientAdherence programs and communication strategies for a smooth market entry. Interested in what data will be collected in Saudi Arabia? Find out more below! #PatientExperience #MarketAccess #ClinicalTrial

For a long time, the Department of Health Abu Dhabi has been making leaps in public health. I'm so excited to see this partnership between Department of Health Abu Dhabi & Children's Hospital of Philadelphia come to life - bring the UAE at the forefront of pediatric oncology care and bringing another avenue for gene therapy companies to expand into our region. #ATMP #MarketAccess #CenterOfExcellence #GeneTherapy #Oncology #CHOP

Delighted with all the ongoings at MENAHTA Forum 2024 yesterday! After months and months of planning, it was so rewarding to see it come to life and receive the overwhelming amount of positive feedback that has come our way. Amongst so many other things, we touched on: 🔎 #HTA archetypes, and what things may look like in Saudi Arabia 👏 The huge successes of the #EJADAH programme in the UAE and what has made value-based decision making feasible in the country 🏨 #LocalLevelHTA at King Hussein Cancer Foundation and Center and what has driven #oncology therapies forward in Jordan Huge huge thank you to our speakers and panelists: ⭐ Dr. Hussain Al-Omar ⭐ Dr. Mohamed Farghaly ⭐ Dr. Abeer Al Rabayah, BSc Pharmacy, MBA, MSc,PMP ⭐ Stephanie Chaccour ⭐ Mohamed Tannira And a big congratulations to our team who brought this to life: ⭐ Kashmira Mangavkar ⭐ Angela M. Acosta Sanchez ⭐ Akansha Patel ⭐ Fawaz Adebayo Abdulazeez ⭐ Shobha Korattikal ⭐ Zoya Ali #MarketAccess #HealthTechnology #EconomicFrameworks #ValueBasedCare

It’s happening!!!! MENAHTA Forum 2024 is TOMORROW! 2 final tickets left - sign up now at www.menahta.com